Healthinvest Partners Ab Exits Position in SciClone Pharmaceuticals (SCLN)

SciClone Pharmaceuticals (SCLN) : Healthinvest Partners Ab has sold out all of its stake in SciClone Pharmaceuticals during the most recent quarter, according to the disclosure filed by the company on Jul 26, 2016 with the SEC. The investment management company has sold out 236,288 shares of SciClone Pharmaceuticals which is valued at $2,483,387.

Other Hedge Funds, Including , Strs Ohio reduced its stake in SCLN by selling 13,700 shares or 19.32% in the most recent quarter. The Hedge Fund company now holds 57,200 shares of SCLN which is valued at $601,172. Louisiana State Employees Retirement System added SCLN to its portfolio by purchasing 22,100 company shares during the most recent quarter which is valued at $232,271. SciClone Pharmaceuticals makes up approx 0.01% of Louisiana State Employees Retirement System’s portfolio.New York State Teachers Retirement System boosted its stake in SCLN in the latest quarter, The investment management firm added 36,921 additional shares and now holds a total of 41,221 shares of SciClone Pharmaceuticals which is valued at $424,576. Nisa Investment Advisors added SCLN to its portfolio by purchasing 1,000 company shares during the most recent quarter which is valued at $13,260.Cutler Group Lp reduced its stake in SCLN by selling 100 shares or 2.36% in the most recent quarter. The Hedge Fund company now holds 4,144 shares of SCLN which is valued at $55,364.

SciClone Pharmaceuticals opened for trading at $10.46 and hit $10.72 on the upside on Friday, eventually ending the session at $10.56, with a gain of 1.44% or 0.15 points. The heightened volatility saw the trading volume jump to 6,34,667 shares. Company has a market cap of $527 M.

On the company’s financial health, SciClone Pharmaceuticals reported $0.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.14 according to the earnings call on Nov 9, 2015. Analyst had a consensus of $0.12. The company had revenue of $42.90 million for the quarter, compared to analysts expectations of $40.61 million. The company’s revenue was up 25.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.17 EPS.

SciClone Pharmaceuticals Inc. (SciClone) is a pharmaceutical company. The Company operates in two geographic segments including China and the rest of the world (the United States and Hong Kong). The Company’s lead product ZADAXIN (thymalfasin) is used for the treatment of hepatitis B virus (HBV) hepatitis C (HCV) as a vaccine adjuvant and certain cancers. Its development portfolio includes Angiomax an anticoagulant indicated in patients undergoing percutaneous coronary intervention (PCI); Neucardin therapeutic drug for the treatment of patients with intermediate to advanced chronic heart failure (CHF); Loramyc a mucoadhesive tablet formulation of miconazole lauriad to treat oropharyngeal candidiasis; Cleviprex a third-generation dihydropyridine calcium channel blocker for the reduction of blood pressure; ProFlow to treat peripheral arterial disease (PAD) and other indications and RapidFilm an oral film formulation of ondansetron to treat nausea induced by chemotherapy.

Leave a Reply

SciClone Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on SciClone Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.